vs

Side-by-side financial comparison of Brookfield Asset Management Ltd. (BAM) and Steris (STE). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $1.1B, roughly 1.4× Brookfield Asset Management Ltd.). Brookfield Asset Management Ltd. runs the higher net margin — 56.7% vs 12.9%, a 43.8% gap on every dollar of revenue.

Brookfield Asset Management Ltd. is a Canadian-American alternative asset manager. The company was founded in December 2022 as a spin-off of the asset management operations of Brookfield Corporation, and manages investments across real estate, infrastructure, renewable energy, private equity, and credit markets globally.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

BAM vs STE — Head-to-Head

Bigger by revenue
STE
STE
1.4× larger
STE
$1.5B
$1.1B
BAM
Higher net margin
BAM
BAM
43.8% more per $
BAM
56.7%
12.9%
STE

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
BAM
BAM
STE
STE
Revenue
$1.1B
$1.5B
Net Profit
$615.0M
$192.9M
Gross Margin
43.8%
Operating Margin
84.2%
18.3%
Net Margin
56.7%
12.9%
Revenue YoY
9.2%
Net Profit YoY
11.2%
EPS (diluted)
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BAM
BAM
STE
STE
Q4 25
$1.1B
$1.5B
Q3 25
$974.0M
$1.5B
Q2 25
$931.0M
$1.4B
Q1 25
$954.0M
$1.5B
Q4 24
$1.4B
Q3 24
$873.0M
$1.3B
Q2 24
$821.0M
$1.3B
Q1 24
$786.0M
$1.1B
Net Profit
BAM
BAM
STE
STE
Q4 25
$615.0M
$192.9M
Q3 25
$692.0M
$191.9M
Q2 25
$584.0M
$177.4M
Q1 25
$507.0M
$145.7M
Q4 24
$173.5M
Q3 24
$537.0M
$150.0M
Q2 24
$124.0M
$145.4M
Q1 24
$373.0M
$-1.4M
Gross Margin
BAM
BAM
STE
STE
Q4 25
43.8%
Q3 25
44.2%
Q2 25
45.1%
Q1 25
43.3%
Q4 24
44.5%
Q3 24
43.6%
Q2 24
44.7%
Q1 24
40.2%
Operating Margin
BAM
BAM
STE
STE
Q4 25
84.2%
18.3%
Q3 25
79.1%
18.2%
Q2 25
70.8%
17.7%
Q1 25
61.0%
14.6%
Q4 24
17.9%
Q3 24
72.5%
16.5%
Q2 24
80.4%
14.5%
Q1 24
56.5%
22.0%
Net Margin
BAM
BAM
STE
STE
Q4 25
56.7%
12.9%
Q3 25
71.0%
13.1%
Q2 25
62.7%
12.8%
Q1 25
53.1%
9.8%
Q4 24
12.7%
Q3 24
61.5%
11.3%
Q2 24
15.1%
11.4%
Q1 24
47.5%
-0.1%
EPS (diluted)
BAM
BAM
STE
STE
Q4 25
$1.96
Q3 25
$1.94
Q2 25
$1.79
Q1 25
$1.48
Q4 24
$1.75
Q3 24
$1.51
Q2 24
$1.46
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BAM
BAM
STE
STE
Cash + ST InvestmentsLiquidity on hand
$1.6B
$423.7M
Total DebtLower is stronger
$1.9B
Stockholders' EquityBook value
$8.9B
$7.2B
Total Assets
$17.0B
$10.6B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BAM
BAM
STE
STE
Q4 25
$1.6B
$423.7M
Q3 25
$1.1B
$319.2M
Q2 25
$480.0M
$279.7M
Q1 25
$332.0M
$171.7M
Q4 24
$155.2M
Q3 24
$172.2M
Q2 24
$10.0M
$198.3M
Q1 24
$207.0M
Total Debt
BAM
BAM
STE
STE
Q4 25
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
BAM
BAM
STE
STE
Q4 25
$8.9B
$7.2B
Q3 25
$8.5B
$7.0B
Q2 25
$8.5B
$7.0B
Q1 25
$8.5B
$6.6B
Q4 24
$6.4B
Q3 24
$9.0B
$6.6B
Q2 24
$3.2B
$6.4B
Q1 24
$2.2B
$6.3B
Total Assets
BAM
BAM
STE
STE
Q4 25
$17.0B
$10.6B
Q3 25
$16.5B
$10.4B
Q2 25
$16.1B
$10.4B
Q1 25
$15.0B
$10.1B
Q4 24
$10.0B
Q3 24
$10.2B
Q2 24
$4.2B
$10.1B
Q1 24
$11.1B
Debt / Equity
BAM
BAM
STE
STE
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BAM
BAM
STE
STE
Operating Cash FlowLast quarter
$562.0M
$298.2M
Free Cash FlowOCF − Capex
$199.5M
FCF MarginFCF / Revenue
13.3%
Capex IntensityCapex / Revenue
6.6%
Cash ConversionOCF / Net Profit
0.91×
1.55×
TTM Free Cash FlowTrailing 4 quarters
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BAM
BAM
STE
STE
Q4 25
$562.0M
$298.2M
Q3 25
$745.0M
$287.8M
Q2 25
$529.0M
$420.0M
Q1 25
$265.0M
$260.8M
Q4 24
$332.8M
Q3 24
$567.0M
$250.7M
Q2 24
$159.0M
$303.7M
Q1 24
$516.0M
$254.8M
Free Cash Flow
BAM
BAM
STE
STE
Q4 25
$199.5M
Q3 25
$201.3M
Q2 25
$326.4M
Q1 25
$189.9M
Q4 24
$243.6M
Q3 24
$148.8M
Q2 24
$195.7M
Q1 24
$163.3M
FCF Margin
BAM
BAM
STE
STE
Q4 25
13.3%
Q3 25
13.8%
Q2 25
23.5%
Q1 25
12.8%
Q4 24
17.8%
Q3 24
11.2%
Q2 24
15.3%
Q1 24
14.6%
Capex Intensity
BAM
BAM
STE
STE
Q4 25
6.6%
Q3 25
5.9%
Q2 25
6.7%
Q1 25
4.8%
Q4 24
6.5%
Q3 24
7.7%
Q2 24
8.4%
Q1 24
8.2%
Cash Conversion
BAM
BAM
STE
STE
Q4 25
0.91×
1.55×
Q3 25
1.08×
1.50×
Q2 25
0.91×
2.37×
Q1 25
0.52×
1.79×
Q4 24
1.92×
Q3 24
1.06×
1.67×
Q2 24
1.28×
2.09×
Q1 24
1.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BAM
BAM

Incentive Fees$452.0M42%
Infrastruture$332.0M31%
Private Equity$174.0M16%
Renewable Power And Transition$66.0M6%
Other$47.0M4%
Management And Advisory Fees$14.0M1%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons